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Background: Chikungunya virus (CHIKV) is an arthropod borne alphavirus of the family Togaviridae. CHIKV is a
reemerging virus for which there is no safe prophylactic vaccine. A live attenuated strain of CHIKV, CHIK181/25,
was previously demonstrated to be highly immunogenic in humans, however, it showed residual virulence causing
transient arthralgia.
Findings: In this study, we demonstrate the complete inactivation of CHIKV181/25 by 1,5 iodonapthyl azide (INA).
No cytopathic effect and virus replication was observed in cells infected with the INA-inactivated CHIKV. However,
a reduction in the INA-inactivated CHIK virus-antibody binding capacity was observed by western blot analysis.
Conclusion: INA completely inactivated CHIKV and can further be explored for developing an inactivated-CHIKV
vaccine.
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Earlier we have shown that 1,5 iodonapthyl azide (INA)
and UV irradiation completely inactivated the Venezuelan
equine encephalitis virus (VEEV) [1,2]. In this study, we
have extended that approach to evaluate the inactivation
of Chikungunya virus (CHIKV). CHIKV is an arthropod
borne alphavirus of the family Togaviridae. It is a ree-
merging virus that has caused wide spread outbreak in
the nations surrounding the Indian Ocean and Africa
since 2004 [3]. Among the alphaviruses, CHIKV is one
of the most important human pathogens due to the fre-
quent outbreaks worldwide, causing large scale morbid-
ity and economic losses. CHIKV infection has been
reported in the travelers returning from the epidemic
regions, thereby indicating a potential of dissemination
to the previously known naïve regions for CHIKV [4].
Further, E1-A226V mutation in the CHIKV strain of
2005–2006 outbreak has increased the susceptibility of
Aedes albopictus, which is endemic to the previously
CHIKV naïve regions [5,6]. Therefore, there is an ever
increasing risk of CHIKV outbreak in the areas such as
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reproduction in any medium, provided the orendemic. Such potential outbreak may be devastating
due to lack of immunity to CHIKV in the endemic
population. There are no specific drugs against CHIKV
and patients are symptomatically treated with non ster-
oid anti-inflammatory drugs [7]. In the absence of anti-
viral drugs, preventive measures that include effective
CHIKV vaccine are urgently needed. The United States
Army had developed and tested a live attenuated strain
of CHIKV, CHIKV181/25 for vaccine application.
CHIKV181/25 demonstrated an excellent immunogenic
profile (98% seroconversion), however, transient arthral-
gia was observed in about 8% of vaccine recipients [8].
Several other approaches such as chimeric CHIKV on
other alphavirus backbone, CHIK virus like particles,
formalin inactivated CHIKV, DNA immunization and
passive immunization with human polyvalent im-
munoglobulin have also been tested [9-13].
INA is a photoactive hydrophobic azide molecule that
sequesters in the hydrophobic domain of the biomem-
branes and binds to the membrane proteins upon irradi-
ation with long wavelength ultra-violet (UV) light. It was
initially used for labeling the biological membranes [14].
Interaction of INA with proteins inactivates the mem-
brane protein while conserving the ectodomain protrud-
ing outside the membrane [15]. This property of INA
has been used to inactivate influenza virus, Ebola virus,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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immunodeficiency viruses and provide potential vaccine
candidates [1,2,15-18]. In this study, we have evaluated
the dose dependent inactivation of CHIKV181/25 by
INA.
CHIKV181/25 was kindly provided by Drs. Parker MD
and Glass PJ of the United States Army Medical Re-
search Institute (USAMRIID), Frederick, MD. INA was
obtained from Dr. Blumenthal RM, NCI, Frederick
under a material transfer agreement. 0.5 mg of sucrose
gradient purified CHIKV was diluted with 1X DPBS and
vortexed to mix and disintegrate the virus clusters.
20 mM INA was then added to make a final concentra-
tion of INA to 50, 100 and 200 μM. The final volume of
the reaction was set at 1.0 ml. Virus + INA suspension
was then irradiated with UV radiation for a total of
5 min as described before [1,2]. Samples were irradiated
with long wavelength UV radiation. A glass filter was
used to filter out the short wavelength UV radiation [1].
Samples were then immediately stored at -800C until
further use. Preliminary screening of virus inactivation
was done by infecting BHK cells with a multiplicity of
infection (MOI) of 1. Cells were observed for virus
induced cytopathic effect (CPE) such as rounding and
sloughing off from the surface and were stained with
0.1% crystal violet solution in 4% neutral buffered forma-
lin. In our previous study, we have used glutathione to
quench the free INA that may be present in the virus
suspension [1]. However, in this study, addition of gluta-
thione alone to the virus suspension resulted in an in-
consistent non-specific inhibition of CHIKV181/25
infectivity (data not shown). Therefore, glutathione was
omitted in the final inactivation experiments in the
present study. Replication of INA-inactivated CHIKV in
BHK cells was also evaluated by CHIKV specific im-
munofluorescence. Briefly, cells were infected with MOI
of 1 and at 48 hr post infection fixed with 1:1 acetone:
methanol for 10 min at room temperature. Slides were
blocked with 1% BSA for 45 min at room temperature
followed by incubation with primary antibody (1:200,
CHIKV hyper-immune mouse ascetic sera, Cata-
log#VR64, ATCC, Manassas, VA) for 1 hr at 370C. Slides
were then washed and secondary antibody (Rhodamine
labeled goat anti-mouse IgG) was added and incubated
for 30 min at 370C. Slides were washed and mounted
using mounting media containing DAPI (Vectastain,
Vector Labs Inc). Virus titer in the cell supernatants
was measured by the standard plaque assay. Viral tran-
scripts in the supernatant from the infected BHK
cells were analyzed by real-time RT-PCR. The primer set
used for the PCR was following; forward primer:
5-GCCAGACACGGAGACGCCAAC-3 and reverse pri-
mer: 5-TGACCCTACTGAGAACAGCAC-3. The primer
set was targeted against the non-structural protein 4gene of CHIKV181/25 with expected amplicon size of
340 bp. Western blot analysis was done to test the anti-
body binding capacity of INA-inactivated CHIKV using
a polyclonal antibody against CHIKV. Briefly, 12.5 μg of
protein for each sample was separated on 4-20% novex
tris-glycine gel (Invitrogen Inc., Carlsbad VA). Protein
bands were transferred on nitrocellulose membrane
(Amhersham Biosciences UK Limited) at 125 mA over-
night at 4°C. Viral proteins were detected by standard
western blot procedure using polyclonal antibody (1:200)
against CHIKV (CHIKV hyper-immune mouse ascitic
sera, Catalog#VR64, ATCC, Manassas, VA) and alkaline
phosphatase conjugated secondary antibody (1:25000
in 1XTBST, goat anti-mouse IgG, Catalog# AP124A,
Chemicon International). Blot was developed using
10 ml substrate for alkaline phosphatase (Catalog#
S3841, Promega Inc., Madison, WI) at room temperature
for 15 min. A complete inactivation of CHIKV by INA
was achieved in virus samples that were treated with
INA in combination with UV irradiation. This group will
now be addressed as INA-inactivated CHIKV through
the rest of manuscript. No CPE was observed in the cells
infected with INA-inactivated CHIKV (Figure 1A). Im-
munofluorescence staining for CHIKV also showed no
viral antigen in the cells infected with INA-inactivated
CHIKV whereas cells infected with non-inactivated
CHIKV were positively stained for CHIKV antigen
(Figure 2). Uninfected cells served as negative controls
for CHIKV staining and infection. Virus titration by
standard plaque assay [2] showed complete absence of
CHIKV in supernatants from the cells infected with
INA-inactivated CHIKV whereas significant viral titers
were measured in the supernatants of cells infected with
non-inactivated CHIKV (Figure 1B). Further, no viral
transcripts were detected in the supernatant of cells
infected with the CHIKV that was inactivated with 50,
100 and 200 μM dose of INA (Figure 1C, detection cut-
off at Ct = 33). Similar results were observed in three re-
petitive experiments. Next, we investigated, if treatment
with INA has any adverse effect on the antigenicity of
CHIKV by western blot analysis. The binding capacity of
the virus to antibody appears to be reduced in INA-
inactivated CHIKV virus samples (Figure 1D).
Our findings are important as CHIKV causes an on-
going outbreak affecting millions of people around the
globe. An effective CHIKV vaccine is urgently needed to
control the spread of CHIKV. Live attenuated CHIKV181/
25 was shown to have an excellent immunogenicity;
however, the clinical trial was halted due to issues with
residual virulence causing transient arthralgia in the
vaccine recipients [7]. The INA-inactivated CHIKV181/
25 formulation may address the issue of residual viru-
lence that is associated with live attenuated CHIKV181/
25. INA-inactivation resulted in a relatively less binding
Figure 1 Inactivation of CHIKV by INA: Inactivation of CHIKV by INA was evaluated as CPE, virus titer and viral RNA transcripts. A: BHK
cells were infected with various test and control samples and virus induced CPE was observed. Cells were stained with 0.1% crystal violet dye in
4% neutral buffered formalin. No CPE was observed in cells infected with INA treated CHIKV in combination with UV irradiation and cells
replicated normally as evident by the stain uptake by the cells similar to control cells without virus infection. Irradiation of CHIKV alone and
treatment with DMSO (since INA stocks were made in DMSO) did not affect the infectivity as evident by the loss of cells in these wells. B: Virus
titer was measured in the supernatant of the cells infected with non-inactivated and INA-inactivated CHIKV. No virus was detected in the
supernatant of INA-inactivated CHIKV and treatment with INA alone did not affect the virus replication. C: Viral transcripts were detected in the
supernatants of cells infected with the non-inactivated and INA-inactivated CHIKV. No viral transcripts were detected in the cells infected with
CHIKV inactivated with 50, 100 and 200 μM dose of INA in combination with UV irradiation. D: Western Blot analysis of the CHIKV proteins
showed low binding of anti-CHIKV polyclonal antibody to CHIKV upon inactivation with INA. 1 = CHIKV; 2 = CHIKV + UV Irradiation; 3 = CHIKV +
INA (200 μM); 4 = CHIKV + INA (50 μM) + UV Irradiation; 5 = CHIKV + INA (100 μM) + UV Irradiation; 6 = CHIKV + INA(200 μM) + UV Irradiation;
and 7 = INA (200 μM) alone. Irr = UV irradiation.
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anti-CHIKV E2 glycoprotein. This raises the question
whether there may be some loss of antigenicity upon in-
activation with INA. However, INA-inactivated CHIKV
may still elicit a protective response against virulent
CHIKV infection as shown with other INA-inactivated
enveloped viruses such as VEEV, Ebola and Influenza
virus. Chemical inactivation of CHIKV for vaccine pur-
poses has been previously reported [11,19]. Formalin
inactivated CHIKV was shown to induce neutralizing
antibody and reduce homologous virulent virus titer [19].
Further testing of INA-inactivated CHIKV in the animal
model will be needed for testing the protective efficacy ofINA-inactivated CHIKV181/25 as a vaccine candidate,
and its advantage over current approaches of generating
inactivated vaccines. To our knowledge this is the first
study to show a complete inactivation of CHIKV181/25
using INA.Abbreviations
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Figure 2 Evaluation of CHIKV inactivation by immunofluorescence: BHK cells were infected with non-inactivated and INA-inactivated
CHIKV and CHIKV specific immunofluorescence was evaluated as described in the text. A: CHIKV; B: CHIKV + UV Irradiation; C: CHIKV +
DMSO; D: CHIKV + DMSO + UV Irradiation; E: CHIKV + INA (50 μM); F: CHIKV + INA (50 μM) + UV Irradiation; G: CHIKV + INA (100 μM), H: CHIKV +
INA (100 μM) + UV Irradiation; I: CHIKV + INA (200 μM); J: CHIKV + INA (200 μM) + UV Irradiation; K: uninfected.
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